Table 1.
Summary of anti-RR autoantibody reactivity in HCV patients treated with interferon-α/ribavirin and telaprevir
| Parameters | Total patients (n = 52) | Anti-RR-positive patients (n = 10) | Anti-RR-negative patients (n = 42) | p value |
|---|---|---|---|---|
| Male | 36 (69%) | 7 (70%) | 29 (69%) | NS |
| Female | 16 (31%) | 3 (30%) | 13 (31%) | NS |
| Age (years) ± SD | 54 ± 9 | 53 ± 14 | 54 ± 8 | NS |
| Genotype 1a# | 12 (23%) | 3 (30%) | 9 (21%) | NS |
| Genotype 1b# | 39 (75%) | 7 (70%) | 32 (76%) | NS |
| Previous IFN/RBV | 32 (62%) | 10 (100%) | 22 (52%) | <0.01 |
| Treatment outcome | ||||
| SVR, no side effects | 35 (67%) | 6 (60%) | 29 (69%) | NS |
| SVR, but side effects | 5 (10%) | 1 (10%) | 4 (10%) | NS |
| SVR, combined | 40 (77%) | 7 (70%) | 33 (79%) | NS |
| Relapse | 5 (10%) | 3 (30%) | 2 (5%) | <0.05 |
| No response | 7 (13%) | 0 (0%) | 7 (17%) | NS |
| Fisher–Freeman–Halton exact test | ||||
| Anti-RR positive vs. anti-RR negative, with SVR separated | NS | |||
| Anti-RR positive vs. anti-RR negative, with SVR combined | <0.05 | |||
Values presented as n (%) unless otherwise indicated
Anti-RR anti-rods/rings autoantibody, IFN/RBV interferon-α/ribavirin therapy, NS not statistically significant (p > 0.05), SD standard deviation, SVR sustained virological response
#One patient without anti-RR was genotype 3b